DocuSign's AI Push Rekindles Interest, But Valuation Still Reflects Skepticism

What happened

Docusign's stock has remained range-bound near $68 despite consistent high-single-digit revenue growth and ~30% free cash flow margins, as investors debate whether AI will disrupt or reinforce its e-signature dominance. A September 2026 MarketBeat article highlights the company's AI push, specifically its Intelligent Agreement Management (IAM) platform, as a reason to rethink the bear case that agentic AI will bypass legacy e-signature tools. The IAM platform, launched in April 2024, had surpassed 25,000 customers and was approaching a low-double-digit share of recurring revenue by the end of fiscal 2026, according to the master report. However, competitive bundling by Microsoft and Adobe remains a credible threat, and the market continues to value Docusign as a mature, ex-growth software utility, with a P/E near 42 and EV/EBITDA around 37. The upcoming first-time disclosure of ARR and IAM as a percentage of ARR, along with fiscal 2027 ARR guidance, will be pivotal in determining whether the AI narrative translates into measurable growth acceleration.

Implication

The news article adds no new quantitative evidence beyond what was already known, so the investment thesis remains unchanged: Docusign is a high-quality cash generator with optionality on IAM-driven re-acceleration, but the stock is not yet pricing in success. If fiscal 2027 ARR guidance lands at or above 10% with IAM disclosed at low-to-mid teens of ARR, the stock could re-rate toward the base case of $80, implying ~17% upside plus buybacks. Conversely, if growth remains stuck at 8% and IAM penetration underwhelms, the stock is likely to stay range-bound or drift lower, with downside cushioned by net cash and strong cash flow. The current price near $68 is close to the master report's attractive entry of $65, suggesting that patient investors can build positions on weakness, but position sizing should remain conservative given competitive and execution risks. The biggest near-term catalyst is the Q4 FY2026 earnings release, which will provide the first official ARR and IAM disclosures, and that event will either validate the AI re-rating thesis or keep the stock in a holding pattern.

Thesis delta

The thesis is unchanged: Docusign remains a POTENTIAL BUY with a base case value of $80, supported by IAM traction and strong free cash flow, but the market still treats it as a mature, low-growth asset. The September 2026 news article reinforces existing evidence of IAM adoption rather than introducing new data, so there is no shift in conviction or valuation scenarios. The critical variable remains whether upcoming ARR guidance shows acceleration above the high-single-digit baseline; until then, we maintain a moderate conviction rating of 3.5 out of 5.